Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Phellinus and tripterygium glycosides in delaying the process of focal segmental glomerulosclerosis

A technology for tripterygium glycosides and glomerulosclerosis, which is applied in the directions of drug combinations, medical preparations containing active ingredients, and pharmaceutical formulations, can solve problems such as non-discovery, reduce toxicity, alleviate renal function damage, and meet clinical needs. desired effect

Active Publication Date: 2021-07-23
HANGHZOU HOSPITAL OF TRADITIONAL CHINESE MEDICINE
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the research on Phellinus Phellinus covers many of the fields mentioned above, and new researches continue to emerge, so far, there are few reports on the research and application of Phellinus Phellinus in the protection of chronic kidney disease at home and abroad. No related records found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Phellinus and tripterygium glycosides in delaying the process of focal segmental glomerulosclerosis
  • Application of Phellinus and tripterygium glycosides in delaying the process of focal segmental glomerulosclerosis
  • Application of Phellinus and tripterygium glycosides in delaying the process of focal segmental glomerulosclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1 Effect of Phellinus and Tripterygium Glycosides on Urinary Protein in FSGS Rats

[0030] Experimental results such as figure 1 As shown, the 24 h urine protein (24 h Pro) in the model group was significantly higher than that in the control group, the 24 h urinary protein in the Phellinus group and each intervention group was lower than that of the model group in the fourth week, and the Phellinus group in the tenth week Compared with the model group, the combined tripterygium glycosides group significantly reduced urinary protein, and Phellinus or Tripterygium glycosides alone could also significantly reduce urinary protein, but there was no statistical significance compared with the model group.

Embodiment 2

[0031] Example 2 Effect of Phellinus and Tripterygium glycosides on renal function in FSGS rats

[0032] Experimental results such as figure 2 As shown, the serum creatinine (Serum creatinine, Scr) and urea nitrogen (Blood urea nitrogen, BUN) of the rats in the model group were significantly higher than those of the control group, and the Scr values ​​of each intervention group were significantly lower than those of the model group. The BUN level of the treatment group was significantly lower than that of the model group, and significantly lower than that of the Phellinus or tripterygium glycosides alone intervention group. There was no statistically significant difference between the BUN level of the single treatment group and the model group.

Embodiment 3

[0033] Example 3 Effect of Phellinus and Tripterygium Polyglycosides on Blood Lipids of FSGS Rats

[0034] The experimental results are shown in Table 1. Serum triglyceride (Tglyceride, TG), cholesterol (Total Cholesterol, TC) and low density lipoprotein (Low density lipoprotein, LDL) in the FSGS nephropathy rat model group were significantly higher than those in the control group. TG and TC in the treatment group were significantly lower than those in the model group, LDL levels in the Phellinus and Tripterygium glycosides group were significantly lower than those in the model group, and TG and LDL levels were significantly lower than those in the Phellinus or Tripterygium glycosides alone intervention group, but there was no statistical difference. significance.

[0035] Table 1

[0036]

[0037] Note: Compared with the normal group, a p b p <0.05.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of the combined application of Phellinus and tripterygium glycosides in delaying the progress of focal segmental glomerulosclerosis. Phellinus radix combined with tripterygium glycosides of the present invention can significantly reduce urine protein, reduce blood creatinine and blood urea nitrogen in rats, reduce serum triglyceride, cholesterol and low-density lipoprotein, reduce creatine kinase and creatine creatine isoenzyme and The amount of alanine aminotransferase. In the present invention, the Phellinus decoction combined with tripterygium glycosides can reduce its toxicity and improve heart damage on the basis of ensuring the original effects of tripterygium glycosides on relieving renal function damage in FSGS rats and reducing blood lipids, and has broad application potential. application prospects.

Description

technical field [0001] The invention relates to the technical field of traditional Chinese medicines, in particular to the use of Phellinus radix and tripterygium glycosides in delaying the progress of focal segmental glomerulosclerosis. Background technique [0002] Chronic kidney disease (chronic kidney disease, CKD) has become a major disease that seriously threatens human health. The latest epidemiological survey results show that the prevalence of CKD in my country is 10.8% (about 120 million). Focal segmental glomerulomerulosclerosis (FSGS) specifically refers to a common primary glomerular disease, with focal and segmental sclerosis as the main pathological features, and the main clinical manifestation is proteinuria , its incidence rate is increasing year by year, and it is very easy to progress to end-stage renal disease (end-stage renal disease, ESRD). Therefore, it is urgent to find a safe and effective method to delay the progress of FSGS. [0003] At present,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/37A61K36/07A61P13/12A61P3/06A61P9/00
CPCA61K36/07A61K36/37A61K2236/331A61P3/06A61P9/00A61P13/12A61K2300/00
Inventor 万凤杨汝春唐玥雯李有贵
Owner HANGHZOU HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com